LEVOCABASTINE is a new Hi-receptor 
Introduction
Given the wide array of therapeutic agents available for the treatment This review will focus on levocabastine, a new H-receptor antagonist, specifically developed for the topical treatment of seasonal allergic rhinoconjunctivitis and a comparison of the therapeutic efficacy of this agent with that of two other widely used and anti-allergic agents, the oral Hi-receptor antagonist terfenadine and the topical mast cell stabilizer sodium cromoglycate. In particular, emphasis will be placed on the comparative efficacy of these different therapeutic approaches for the treatment of seasonal allergic rhinoconjunctivitis on days with high pollen counts (defined as greater than or equal to 50 pollen particles/m3).
Levocabastine versus sodium cromoglycate:
A number of clinical trials have demonstrated that topical levocabastine is significantly more effective than sodium cromoglycate for the treatment of seasonal allergic rhinoconjunctivitis, [2] [3] [4] [5] However, in only two of these trials were periods of high pollen counts sufficiently long to permit separate analysis of therapeutic efficacy as a function of the pollen count. 2'5 Although these were independent trials, the study protocols were similar. Both were doubleblind, parallel-group trials in patients with seasonal allergic conjunctivitis, with or without concurrent nasal symptoms. Patients were randomized to receive either levocabastine (0.5 mg/ ml), sodium cromoglycate (20 mg/ml) or matching placebo eye drops at a dose of one drop in each eye four times daily for a period of 4 weeks. Both the patients and the investigators were required to provide global evaluations of therapeutic efficacy at the end of the trial. In addition, the investigators assessed a range of typical symptoms including ocular irritation, itching, redness, lacrimation and eyelid oedema, at the start of the trial, after 2 weeks of treatment and at the end of the study. Symptom severity (C) To date, three independent, randomized, This is of interest, as levocabastine was only double-blind, double-dummy, parallel-group trials administered ocularly and systemic absorption of have been published which assess the comparalevocabastine is reported to be minimal following tive efficacy of topical levocabastine and oral ter- to receive either levocabastine eye drops (0.5 mg/ml, one drop in each eye twice daily) and nasal spray (0.5 mg/ml, two puffs in each nostril twice daily) plus a twice daily oral placebo or to receive oral terfenadine (60 mg twice daily) in combination with placebo eye drops and nasal spray for a total of 8 weeks.
Both the patients and the investigators performed a global evaluation of therapeutic efficacy at the end of the study period. In addition, the investigators rated the severity of ocular symp- basis using a VAS (0 absent, 100 severe).
The results of these studies show that levocaperiod, levocabastine was consistently more bastine eye drops and nasal spray are at least as effective than oral terfenadine at controlling effective as oral terfenadine for the treatment of symptoms of seasonal allergic rhinoconjunctivitis. this allergic condition and statistically significant The incidence of severe lacrimation and ocular differences in favour of topical levocabastine itching was significantly lower in the levocabaswere reported even though patients in the terfe-tine group on days with high pollen counts (p < nadine group also benefited from the use of 0.05), while the percentage of days free from placebo eye drops and nasal spray. In particular, ocular and nasal itching (p < 0.05) and lacrimathe available data suggest that topical levocabastion (p < 0.01) was significantly higher (Fig. 4) .
tine is more effective than oral terfenadine on These findings are supported by those of a days with high pollen counts. <s A total of 115 smaller trial initiated primarily to assess the tolerpatients with a documented history of grass and/ ability of levocabastine eye drops. In this study, or birch pollen-induced allergic rhinoconjunctivi-13 patients were randomized to receive topical tis participated in the larger of these two trials, 8 levocabastine while 14 were treated with oral ter-58 of whom were randomized to receive topical fenadine. Use of oral medication and eye drops levocabastine. Both treatment regimens were was mandatory, however, patients were requested well-tolerated and the incidence and type of only to use the nasal spray as required. The use adverse reactions were similar in the two treatof nasal spray was lower in the levocabastine ment groups, group (46%) than in the terfenadine group Global evaluations of therapeutic efficacy (56%), suggesting that topical levocabastine was revealed a consistent, yet non-significant, trend in more effective at relieving nasal symptoms than favour of the topical approach. However, after 4 oral terfenadine. weeks of treatment, investigator assessments
In all, 88% of levocabastine-treated patients revealed that the severity of ocular redness and considered the effect of treatment on ocular the most severe ocular symptom were sigsymptoms to be excellent or good compared nificantly lower in the levocabastine group than with 75% of those who received terfenadine, in the terfenadine group (p < 0.01 and p< 0.05, while 75% of patients in each group were satisrespectively). Analysis of the patients' diaries fled with the effect of the study medication on revealed that VAS ratings were significantly lower nasal symptoms. Investigator assessments in the levocabastine group for ocular and nasal revealed that symptom severity was consistently itching (p < 0.05), lacrimation (p 0.001)and lower in the levocabastine treatment group. In the most severe ocular symptom (p < 0.05). In particular, the severity of ocular itching was sigaddition, the 
